ArticleJournal of health, population, and nutrition2026
State of human papilloma virus vaccine uptake among girls (15-21 years) in Zambia: analysis of a 2024 national survey.
Article in Journal of health, population, and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organisation recommends that countries will achieve at least a 90% human papilloma virus (HPV) vaccine uptake by the year 2030. Tracking the performance of Zambia is necessary to inform programme implementation and ensuring equitable coverage. This study estimates the prevalence of HPV vaccine uptake in Zambia, and examines its associated factors.
methodsData from the 2024 Zambia demographic and health survey was analysed (n = 3,942 girls aged 15–21). Analyses accounted for the complex survey design using sampling weights, clustering, and stratification. Multivariable logistic regression was computed in STATA 14. The adjusted odds ratio and 95% confidence intervals were reported. Statistical significance was set at p < 0.05.
resultsOverall, 61.8% (95%CI: 59.8–63.5) of the participants had ever received HPV vaccine. Among respondents who reported ever receiving the HPV vaccine, 46.3% and 53.2% had received one dose and two doses, respectively. HPV vaccine uptake was higher among girls with primary education (AOR = 4.45; 95%CI: 2.91–6.79), those with secondary/higher education (AOR = 9.08; 95%CI: 5.86–14.05) compared with those with no formal education. Exposure to family planning messages was positively associated with vaccineuptake (AOR = 1.32; 95%CI: 1.12–1.55). Initiation of sexual activity was inversely associated with vaccination, both for debut before age 15 (AOR = 0.79; 95%CI: 0.64–0.99) and at age 15 years or older (AOR = 0.77; 95%CI: 0.66–0.90). Higher odds of vaccination were found among girls from middle-wealth households (AOR = 1.27; 95%CI: 1.01–1.60). Rural dwelling girls had higher odds of HPV vaccination than their urban counterparts (AOR = 1.42; 95%CI: 1.15–1.75). There were lower odds of HPV vaccine uptake in Copperbelt (AOR = 0.72; 95%CI: 0.54–0.96), Lusaka (AOR = 0.70; 95%CI: 0.52–0.93), and Muchinga (AOR = 0.68; 95%CI: 0.50–0.94), while higher odds were observed in Southern Province (AOR = 1.40; 95%CI: 1.05–1.87) compared with Central Province.
conclusionTo ensure equitable coverage, the Zambian Ministry of Health must intensify vaccine availability and access, particularly among girls with no formal education, those residing in poorer households and girls in urban areas. Family planning education campaigns and mass media platforms can be leveraged to raise HPV vaccine awareness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.